[The changes of serumal eosinophil cationic protein of patients with allergic rhinitis with specific immunotherapy]

To approach therapeutic effect and mechanism of specific immunotherapy (SIT) by observing the changes of serumal eosinophil cationic protein (ECP) of allergic rhinitis patients.

Fifty-two patients with allergic rhinitis were enrolled in our research. Thirty-two were randomly divided into SIT group, and twenty were randomly divided into control group. SIT group were treated by sublingual administration of allergen (SLIT), and control group were treated by nasal spray of budesonide. Serumal ECP was measured before and after treatment.

The levels of serumal ECP were respectively (26.2 +/- 5.9) microg/L and (27.4 +/- 6.3) microg/L in both groups of control group and treatment group before treatment. There was no significant difference (P > 0.05) in the two group. The levels after treatment were respectively (18.3 +/- 3.4) microg/L and (23.2 +/- 3.7) microg/L and significant difference was found in the two group (P < 0.01). The levels of serumal ECP were lower than those before treatment in the two groups (SLIT group P < 0.01, control group P < 0.05).

SIT could cut down effectively the levels of serumal ECP with reducing the eosinophil granulocyte aggregation and activation.